BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 23379766)

  • 1. Severe community-acquired pneumonia treated with β-lactam-respiratory quinolone vs. β-lactam-macrolide combination.
    Karhu J; Ala-Kokko TI; Ohtonen P; Syrjälä H
    Acta Anaesthesiol Scand; 2013 May; 57(5):587-93. PubMed ID: 23379766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
    Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
    JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
    Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
    Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospital and long-term outcomes of ICU-treated severe community- and hospital-acquired, and ventilator-associated pneumonia patients.
    Karhu J; Ala-Kokko TI; Ylipalosaari P; Ohtonen P; Laurila JJ; Syrjälä H
    Acta Anaesthesiol Scand; 2011 Nov; 55(10):1254-60. PubMed ID: 22092131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
    Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
    Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIRO score for community-acquired pneumonia: a new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia.
    Rello J; Rodriguez A; Lisboa T; Gallego M; Lujan M; Wunderink R
    Crit Care Med; 2009 Feb; 37(2):456-62. PubMed ID: 19114916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
    Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
    Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
    Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
    J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mortality prediction in community-acquired pneumonia requiring mechanical ventilation; values of pneumonia and intensive care unit severity scores.
    Aydoğdu M; Ozyilmaz E; Aksoy H; Gürsel G; Ekim N
    Tuberk Toraks; 2010; 58(1):25-34. PubMed ID: 20517726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
    Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
    JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the Infectious Diseases Society of America/American Thoratic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care.
    Chalmers JD; Taylor JK; Mandal P; Choudhury G; Singanayagam A; Akram AR; Hill AT
    Clin Infect Dis; 2011 Sep; 53(6):503-11. PubMed ID: 21865188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis.
    Lee JH; Kim HJ; Kim YH
    J Korean Med Sci; 2017 Jan; 32(1):77-84. PubMed ID: 27914135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.